Skip to main content
2022 Guide to Patient Support Services

Y-mAbs Therapeutics

2022 Oncology Guide to Patient Support Services

Y-mAbs Therapeutics


Y-mAbs Therapeutics offers Y-mAbs Connect to assist patients while taking Danyelza (Table).

Y-mAbs Connect

Y-mAbs Connect is a patient support program that provides information about access, insurance, financial support programs, and other resource programs for qualifying patients. Y-mAbs Connect offers a Co-pay Program for eligible patients who are commercially insured, determines patient eligibility for a Patient Assistance Program, and provides Y-mAbs Connect Case Managers to help support your patients.

Co-pay Program

Patients with commercial health insurance may be eligible to receive Danyelza at no cost. Patients may be eligible if they:

  • Have commercial or private insurance and are actively insured at the time of treatment
  • Do not participate in federal- or state-funded healthcare programs, including, but not limited to, Medicare, Medicaid, Medigap, CHAMPVA, Veterans Affairs, Department of Defense, TRICARE, or Children’s Health Insurance Program
  • Are not a cash-paying patient
  • Reside in the United States or a US territory.

Patient Assistance Program

If your patient is uninsured or rendered underinsured for Danyelza, the Patient Assistance Program may be able to provide Danyelza at no cost. Patients may be eligible if they:

  • Are enrolled in Y-mAbs Connect
  • Have been prescribed Danyelza for an FDA-approved indication
  • Are uninsured or underinsured
  • Reside in the United States or a US territory
  • Have an annual household gross income (before taxes and deductions) of ≤600% of the federal poverty level based on household size.

Y-mAbs Connect Case Managers

Once enrolled in Y-mAbs Connect, a case manager will contact your patient and provide information on insurance coverage, financial support programs, and travel support programs.

Click here to enroll your patients in Y-mAbs Connect.

TABLE Y-mAbs Therapeutics Oncology Drug

Patient support programs

Danyelza (naxitamab-gqgk)
In combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy
Patient support program

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"